Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $553.83, for a total value of $5,261,385.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,437,314.79. This trade represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

United Therapeutics stock opened at $540.05 on Wednesday. The stock has a market capitalization of $22.93 billion, a P/E ratio of 19.94, a P/E/G ratio of 1.77 and a beta of 0.57. The company’s fifty day moving average price is $566.86 and its 200 day moving average price is $516.87. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.63 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 26.92 EPS for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research reports. HC Wainwright raised their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Bank of America raised their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. AE Wealth Management LLC increased its stake in United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC raised its position in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $444,000. Tobam lifted its stake in shares of United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock valued at $3,205,000 after purchasing an additional 4,953 shares during the last quarter. Finally, Leuthold Group LLC grew its holdings in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after purchasing an additional 3,126 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.